Table 4.
Antibiotic susceptibility profiles of NMEC and HFEC. Number of isolates (stated as percentages) in NMEC and HFEC were categorized as Sensitive (S), Intermediate (I) or Resistant (R) according to CLSI standards
| Antibiotic | NMEC | HFEC | ||||
|---|---|---|---|---|---|---|
| S | I | R | S | I | R | |
| Ampicillin | 50.94 | 3.773585 | 45.28 | 64.58 | 4.167 | 31.25 |
| Cefazolin | 96.23 | 0 | 3.77 | 93.75 | 0 | 6.25 |
| Cefepime | 96.23 | 0 | 3.77 | 100 | 0 | 0 |
| Cefotaxime | 90.57 | 0 | 9.43 | 93.75 | 0 | 6.25 |
| Cefoxitin | 90.57 | 0 | 9.43 | 95.83 | 2.08 | 2.08 |
| Cefpodoxime | 90.57 | 0 | 9.43 | 9.16 | 0 | 8.33 |
| Ceftazidime | 90.57 | 0 | 9.43 | 93.75 | 0 | 6.25 |
| Ceftriaxone | 88.68 | 1 | 9.43 | 91.66 | 2.08 | 6.25 |
| Cephalothin | 100 | 0 | 0 | 100 | 0 | 1 |
| Ciprofloxacin | 100 | 0 | 0 | 100 | 0 | 0 |
| Gentamicin | 100 | 0 | 0 | 100 | 0 | 0 |
| Imipenem | 100 | 0 | 0 | 100 | 0 | 0 |
| Meropenem | 100 | 0 | 0 | 100 | 0 | 0 |
| Piperacillin/Tazobactam | 100 | 0 | 0 | 100 | 0 | 0 |
| Ceftazidime/Clavulanic acid | 100 | 0 | 0 | 100 | 0 | 0 |
| Amikacin | 100 | 0 | 0 | 100 | 0 | 0 |
| Amoxicillin | 100 | 0 | 0 | 60.41 | 2.083 | 37.5 |
| Chloramphenicol | 94.34 | 0 | 5.66 | 97.91 | 2.083 | 0 |
| Sulfa/Trimethoprim | 81.13 | 0 | 18.86 | 93.75 | 0 | 6.25 |
| Kanamycin | 86.79 | 2 | 9.433 | 100 | 0 | 0 |
| Nalidixic acid | 96.23 | 0 | 3.773 | 81.25 | 0 | 18.75 |
| Sulfisoxazole | 67.92 | 3 | 14 | 68.75 | 16.66 | 14.58 |
| Tetracycline | 81.13 | 0 | 10 | 91.66 | 0 | 8.33 |